Investigational Drug Information for Rigosertib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Rigosertib?
Rigosertib is an investigational drug.
There have been 29 clinical trials for Rigosertib.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Syndrome, and Preleukemia. The leading clinical trial sponsors are Onconova Therapeutics, Inc., Icahn School of Medicine at Mount Sinai, and The Leukemia and Lymphoma Society.
Summary for Rigosertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 498 |
| WIPO Patent Applications | 443 |
| Japanese Patent Applications | 149 |
| Clinical Trial Progress | Phase 3 (2011-05-01) |
| Vendors | 37 |
Recent Clinical Trials for Rigosertib
| Title | Sponsor | Phase |
|---|---|---|
| Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC | Onconova Therapeutics, Inc. | Early Phase 1 |
| Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC | Thomas Jefferson University | Early Phase 1 |
| Rigosertib for RDEB-SCC | Prof. Johann Bauer | Phase 1/Phase 2 |
Clinical Trial Summary for Rigosertib
Top disease conditions for Rigosertib
Top clinical trial sponsors for Rigosertib
US Patents for Rigosertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
